132 related articles for article (PubMed ID: 9612597)
41. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
42. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Huland E; Heinzer H; Huland H
Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
[TBL] [Abstract][Full Text] [Related]
43. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
Satake I; Tari K; Nakagomi K; Ozawa K
Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
[TBL] [Abstract][Full Text] [Related]
44. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M
J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500
[TBL] [Abstract][Full Text] [Related]
46. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
47. [Clinical trial of inhalant recombinant interferon-gamma in patients with pulmonary metastasis from renal tumor (preliminary report)].
Kawata N; Takimoto Y; Hirakata H; Fuse T; Hirano D; Yamanaka Y
Hinyokika Kiyo; 1994 Sep; 40(9):773-6. PubMed ID: 7801837
[TBL] [Abstract][Full Text] [Related]
48. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
49. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Taylor W; Laszlo J
Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
[TBL] [Abstract][Full Text] [Related]
51. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
52. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
Kawata N; Ono M; Endo M; Ichinose T; Hamada T; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
[TBL] [Abstract][Full Text] [Related]
53. Subcutaneously administered recombinant interferon-gamma in humans: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages, blood neutrophils, and monocytes.
Halme M; Maasilta P; Repo H; Leirisalo-Repo M; Taskinen E; Mattson K; Cantell K
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):283-91. PubMed ID: 8061901
[TBL] [Abstract][Full Text] [Related]
54. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
Kaplan LD; Abrams DI; Sherwin SA; Kahn J; Volberding PA
Biotechnol Ther; 1989-1990; 1(3):229-36. PubMed ID: 2562651
[TBL] [Abstract][Full Text] [Related]
55. [Effect of recombinant alpha-interferon on advanced renal cell carcinoma].
Isaka S; Okano T; Akimoto S; Shimazaki J; Murakami S; Igarashi T; Kitamura Y; Yamaguchi K; Kataumi S; Ohtsuka K
Hinyokika Kiyo; 1985 Dec; 31(12):2209-14. PubMed ID: 3832921
[TBL] [Abstract][Full Text] [Related]
56. [Interferon alpha and gamma in the treatment of renal cell carcinoma].
Kawai K; Sato K; Nishijima Y; Sasaki A; Yamashita J; Ishikawa H; Koiso K
Nihon Jinzo Gakkai Shi; 1990 Feb; 32(2):231-6. PubMed ID: 2112656
[TBL] [Abstract][Full Text] [Related]
57. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
[TBL] [Abstract][Full Text] [Related]
58. High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Fyfe G
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S70-2. PubMed ID: 9457398
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of various malignancies with recombinant IFN-gamma (S-6810). The IFN-gamma Study Group].
Takaku F
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):645-52. PubMed ID: 3030197
[TBL] [Abstract][Full Text] [Related]
60. [Gamma interferon therapy of cancer patients].
Kobayashi Y; Urabe A
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):804-9. PubMed ID: 3133983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
